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in Blood challenges, on the basis of observations on cell lines, the concept that erythropoietin has activities unrelated to erythrodiff erentiation. Sinclair and colleagues, based at Amgen, have published six papers since 2006 focused on whether the erythropoietin receptor (EPOR) is expressed by tumour cells-a fact that, if true, could have adverse eff ects for the use of erythropoietin in cancer. They conclude that EPOR is not expressed by many of the cells previously reported to express EPOR and exhibit cytoprotection by erythropoietin, and question the entire concept that erythro poietin is active on non-haemopoietic cells.
Although sometimes data from one laboratory are not replicated in another, many investigators have reported trophic or antiapoptotic eff ects of eryth ro poietin on many cells, including those that Sinclair and collea gues report in tabular form without presenting their original data. In fact, over the past 10 years, multiple investigators have shown that erythropoietin is tissue-protective, anti-infl ammatory, and promotes neuro genesis and angio genesis.
The observation that erythro poietin is neuroprotective in vivo 2 ignited substantial interest in its roles and possible therapeutic use in various diseases. Searching for "erythropoietin AND protect*", PubMed gives 863 hits of which we identifi ed 346 research papers reporting a protective or reparative action, and only ten a lack of extra-haemopoietic eff ects.
Having no data to compare with previous studies, it is diffi cult to under stand whether "inconsistent, irreproducible and at best modest (10-20%) eff ects" 1 refers to the inconsistency of the eff ect or to Sinclair and colleagues' experimental technique.
Sinclair and colleagues expand their conclusions further by stating that in vivo studies of erythropoietin in animal models of damage are faulty and that they "do not believe [that] clinical studies examining an alleged 'direct' eff ect of ESAs [erythropoiesisstimulating agents] on heart or brain function or repair are well founded".
The term "alleged" is a hyperbole when referring to the tissueprotective actions of erythropoietin that, independ ently of the receptors implicated, are supported by hundreds of studies, two meta-analyses, 3,4 and some clinical trials, although we agree that caution should be used because of potential side-eff ects. Cratylus, discussing with Plato, stated that names express the essence of the thing. This is hardly the case for cytokines: look at tu mour necrosis factor or inter leukin 1. Although, from a pharma ceutical perspective, it would be con venient if erythropoietin had no activities outside erythropoiesis, this is wishful thinking. The fi eld would be better served by eff orts to understand the full spectrum of erythropoietin's actions.
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